Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $3.59B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +10 vs. previous quarter
- 293
- 13F valueReported value at the end of Q2 2026
- $1.19B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $263.5M
- +60.6% year over year
- Net income, FY2025
- -$391.0M
- No comparable prior period
- Free cash flow, FY2025
- -$336.2M
- No comparable prior period
- Revenue, Q3 FY2026
- $121.5M
- +80.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $391.0M (148.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 65.2M
- Shares sold short
- Change
- +6.26M
- +10.6% vs. previous
- Days to cover
- 4.17
- At average daily volume
Superinvestors holding IOVA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding IOVA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Iovance Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2025 (view filing) | Jun 5 | 1 day | Kirby Daniel GordonChief Commercial Officer | PPurchase | +30.0K | $1.84 | +$55.2K | New position30.0K after | |
| May 27, 2025 (view filing) | May 23 | 4 days | Puri Raj K.Chief Regulatory Officer | PPurchase | +5.60K | $1.74 | +$9.74K | +2.8%206.9K after | |
| May 16, 2025 (view filing) | May 14 | 2 days | Vogt Frederick GInterim CEO & General Counsel | PPurchase | +25.0K | $1.69 | +$42.3K | +7.2%374.6K after | |
| Nov 14, 2024 (view filing) | Nov 12 | 2 days | Maynard Ryan DDirector | SSale | −50.0K | $10.06 | −$503.0K | −87.0%7.50K after | |
| Feb 20, 2024 (view filing) | Feb 20 | Same day | McPeak Merrill ADirector | PPurchase | +250.0K | $9.15 | +$2.29M | +356.4%320.1K after | |
| Feb 20, 2024 (view filing) | Feb 20 | Same day | Dukes Iain D.Director | PPurchase | +32.0K | $9.15 | +$292.8K | +145.5%54.0K after | |
| Feb 20, 2024 (view filing) | Feb 20 | Same day | Rothbaum Wayne P.Director | PPurchase | +5.00M | $9.15 | +$45.8M | +21.7%28.1M after | |
| Sep 19, 2023 (view filing) | Sep 18 | 1 day | McPeak Merrill ADirector | PPurchase | +10.0K | $5.56 | +$55.6K | +4.2%248.6K after | |
| Sep 15, 2023 (view filing) | Sep 15 | Same day | Rothbaum Wayne P.Director | PPurchase | +5.00M | $5.30 | +$26.5M | +27.7%23.1M after | |
| Dec 22, 2022 (view filing) | Dec 21 | 1 day | McPeak Merrill ADirector | PPurchase | +10.0K | $6.15 | +$61.5K | +16.6%70.2K after |
Top 10 13F holders, Q2 2026
See all 293 holdersThe largest institutional positions in Iovance Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 36,957,681 | $153.7M | 0.00% | +5,877,176+18.9% | Added |
| MHR Fund Management LLC | 28,967,103 | $120.5M | 6.28% | 00.0% | Unchanged |
| State Street Corp | 24,478,268 | $101.8M | 0.00% | +7,030,160+40.3% | Added |
| Two Sigma Investments, LP | 19,010,697 | $79.1M | 0.06% | +5,323,264+38.9% | Added |
| Vanguard Capital Management LLC | 18,204,248 | $75.7M | 0.00% | +1,586,511+9.5% | Added |
| Vanguard Portfolio Management LLC | 14,388,999 | $59.9M | 0.00% | +2,688,155+23.0% | Added |
| Geode Capital Management, LLC | 10,324,826 | $43.0M | 0.00% | +1,752,228+20.4% | Added |
| Millennium Management LLC | 8,525,919 | $35.5M | 0.02% | −888,373−9.4% | Reduced |
| Dimensional Fund Advisors LP | 6,460,449 | $26.9M | 0.00% | +3,814,747+144.2% | Added |
| Palo Alto Investors LP | 5,296,209 | $22.0M | 3.04% | −1,053,354−16.6% | Reduced |
Holders of 5% or more of IOVA
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Iovance Biotherapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.50%33.4M shares | +1.10 ppfrom 6.40% | Jul 17, 20252 filings | Jul 28, 2026 | SEC |